PFIZER INC (PFE)
US7170811035 - Common Stock
PFIZER INC
NYSE:PFE (9/28/2023, 8:43:10 AM)
31.94
-0.16 (-0.5%)
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 83,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The firm operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
Company Info
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK 10017
P: 12127332323.0
CEO: Albert Bourla
Employees: 83000
Website: https://www.pfizer.com/
PFE News
an hour ago - Yahoo FinanceGSK lifts growth ambitions for HIV business on long-acting drugGSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating the infection. The ViiV business, in which Pfizer and Shionogi hold small stakes, is a key element of a push by group CEO Emma Walmsley to improve investor confidence in the strength of GSK's drug development pipeline, which has lagged rivals. Strong sales of medicines for HIV, the virus that causes AIDS, were one of the drivers behind the company's improved guidance for 2023 earnings, issued in July, alongside continued growth in demand for GSK's shingles vaccine.
3 hours ago - InvestorPlaceSmart Picks: 7 Blue-Chips Trading Below True ValueUndervalued blue-chip stocks make more sense than ever as the tech sell off causes a pivot into more conservative shares.
4 hours ago - The Business JournalsThe Petri Dish: Ginkgo, Pfizer sign $331M deal; Leqembi OK'd in Japan
8 hours ago - IssueWireKevin Dodelande's iMi launches into early cancer detectionIn this age of technological advances, the power of Big Data combined with Artificial Intelligence (AI) is opening up new possibilities through early diagnosis to increase patient life expectancy.
18 hours ago - Market News VideoNotable Wednesday Option Activity: LITE, BXP, PFE
19 hours ago - InvestorPlaceDon’t Miss the Boom: 3 Pharma Stocks Set to Explode HigherThese pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher.
PFE Twits
Here you can normally see the latest stock twits on PFE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
